Roche-AC Immune's Crenezumab Fails To Show Benefit In Sub-Set Of Alzheimer's Patients

Roche Holdings AG RHHBY said its Alzheimer's medicine crenezumab did not slow or prevent cognitive decline in people with a specific genetic mutation that causes early-onset disease.
Crenezumab did not show a statistically significant clinical benefit in its co-primary endpoints assessing the rate of change in cognitive abilities or episodic memory function.
The Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia Trial evaluated the potential of crenezumab in 252 people.
Minor numerical differences favoring crenezumab were observed across the co-primary and multiple secondary and exploratory endpoints, but these were not statistically significant.
No new safety issues were identified. Further analyses of data are ongoing.
Initial data will be presented at the Alzheimer's Association International Conference in August.
Within its Alzheimer's pipeline, Roche is also evaluating gantenerumab in autosomal dominant Alzheimer's disease, as well as for preventing sporadic Alzheimer's and treating early Alzheimer's in late-stage trials.
The phase 3 GRADUATE studies results of gantenerumab in early Alzheimer's are expected in Q4, 2022.
Crenezumab is an investigational treatment discovered by AC Immune SA ACIU and designed to neutralize a pathological species of the beta-amyloid protein called oligomers.
It was developed by Genentech, a member of the Roche Group, under a license and collaboration agreement established in 2006.
Price Action: ACIU shares are down 27.62% at $2.07 during the premarket session on the last check Thursday. RHHBY shares closed at $38.53 on Wednesday.

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga